Karuna Gears Up To File KarXT, A Schizophrenia ‘Gamechanger’
Free From Serious Side-Effects Of Standard Treatment
Executive Summary
New CEO Bill Meury said Karuna had plenty of time, money and physician enthusiasm to ensure a US launch in 2024 would be a success.
You may also be interested in...
Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue
Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.
New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.
Continuity Or Change? Roche’s New CEO And Pharma Leader Take On Big Strategy Question
Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.